```
Performance of Gazelle COVID-19 point-of-care test for detection of nucleocapsid antigen
 1
      from SARS-CoV-2
 2
 3
      Running Title: Point-of-care diagnostic for Covid-19
 4
 5
      Amrish Mehta<sup>1</sup>, Bri Spencer<sup>2</sup>, Ashok Garg<sup>3</sup>, Pradeep Kalmorge<sup>4</sup>, Raúl A. Ocasio Gonzalez<sup>5</sup>,
 6
      Kate Taussig<sup>5</sup>, Ryan R. Fortna<sup>2*</sup>
 7
 8
 9
      Affiliations:
      <sup>1</sup>Apple Diagnostics, Ghatkopar, Mumbai
10
      <sup>2</sup>Northwest Laboratory, Bellingham, WA, USA
11
      <sup>3</sup>Acu-MDx Laboratory and Research Center Pvt. Ltd Diagnostics, Ghatkopar West, Mumbai
12
      <sup>4</sup>Bio Diagnostics Laboratory, Pune
13
      <sup>5</sup>Hemex Health, Portland, USA
14
15
16
      Correspondence: *Ryan R. Fortna
17
      Email: Ryan.Fortna@nwpathology.com
18
19
      3548 Meridian Street, Suite 101
      Bellingham, WA 98225
20
      (360) 527-4580
21
22
      Abstract Word count: 148
23
24
      Body of the Text Word Count: 2090
25
26
27
28
29
30
31
```

32 Abstract:

34	SARS-CoV-2 antigen assays offer simplicity and rapidity in diagnosing COVID-19. We assessed
35	the clinical performance of Gazelle COVID-19 test, a fluorescent lateral flow immunoassay with
36	an accompanying Reader utilizing image-recognition software for detection of nucleocapsid
37	antigen from SARS-CoV-2. We performed a prospective, operator-blinded, observational study
38	at 2 point-of-care (POC) sites. Nasal swab specimens from symptomatic patients were tested
39	with Gazelle COVID-19 test and real-time polymerase chain reaction (RT-P CR) assay. Overall,
40	data from 1524 subjects was analyzed, and 133 were positive by RT-PCR. Mean (range) age of
41	participants was 34.7 (2-94) years and 570 (37.4%) were female. The sensitivity and the
42	specificity of the Gazelle COVID-19 test were 96.3% and 99.7%. The PPV of Gazelle COVID-
43	19 test was 97.0%, NPV 99.6%, and accuracy 99.4%. In POC settings, Gazelle COVID-19 test
44	had high diagnostic accuracy for detection of SARS-CoV-2 in nasal swab samples of
45	symptomatic subjects suspected of COVID-19.
46	
47	Keywords: COVID-19; SARS-CoV-2; immunoassay, RT-PCR, detection
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	

63

64

65 **INTRODUCTION**

66

The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), the 67 disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic 68 69 health emergency [1]. The high rate of community and institutional transmission [2] of SARS-CoV-2 infection underscores the need for rapid and accurate detection of active infection. In a 70 survey of unmet needs for COVID-19 tests in health and social care settings, hospitals identified 71 COVID-19 testing as the second highest unmet need, with the greatest priority being a test for 72 73 symptomatic patients presenting to hospitals for infection control [3]. Studies have shown that of 74 the various steps required in the process of testing and diagnosing an active infection, minimizing testing delay had the largest impact on reducing onward transmissions [4, 5]. 75 76 Current diagnostic tests for the SARS-CoV-2 detect either nucleic acid or antibody of viral 77 protein [6]. Several molecular assays based on reverse transcriptase polymerase 78 chain reaction (RT-PCR) have been developed to detect and quantify SARS-CoV-2 RNA. 79 However, COVID-19 patients can continue to shed viral RNA well beyond clinical recovery and 80 positive RT-PCR does not necessarily indicate infectiousness [7]; RT-PCR testing detects residual genome, and a test of actual infectivity (viable virus) is needed. Furthermore, RT-PCR is 81 82 expensive, has a relative long turn-around-time, require trained personnel, and is often available only in laboratory set-ups that provide centralized services. In February 2020, WHO identified 83 84 rapid testing with point-of-care (POC) diagnostics as a number one priority to address the COVID-19 pandemic [8] and the US Food and Drug Administration (FDA) permitted licensed 85 86 laboratories to report in-house developed SARS-CoV-2 diagnostic tests [9]. The Gazelle COVID-19 Test is a fluorescent lateral flow immunoassay (FIA) for the qualitative 87 detection of nucleocapsid antigen from SARS-CoV-2. The Gazelle platform includes a Reader 88 89 which is capable of reading both colorimetric and certain fluorescent lateral flow assays and is 90 adapted from the commercially available hemoglobin variant reader, using derived imagerecognition software [10]. Here, we present the results from an observational study to assess the 91 92 diagnostic performance of Gazelle Covid-19 Test, compared to RT-PCR.

93

94 METHODS

95 Study Design and Population

96 We conducted a prospective, observational study to determine the diagnostic performance of Gazelle Covid-19 Test, compared to RT-PCR. The study was conducted in two different regions 97 from 23 August 2021 through 12 November 2021. The first site was at Northwest Laboratory's 98 COVID-19 drive-through screening site located at the Bellingham Airport, Washington, USA 99 100 and the second one was at Bio Diagnostics laboratory, Pune and Acu-MDx Laboratory and Research Center Pvt. Ltd Diagnostics Lab, Mumbai, India. The objective of the study was to 101 102 assess Gazelle COVID-19 Test performance (positive percent agreement [PPA] and negative percent agreement [NPA]) in comparison to RT-PCR using dual mid-turbinate nasal swab 103 104 samples from symptomatic subjects (within five days of onset of symptoms) at point of care. 105 Participants were recruited, screened, and enrolled by the Investigator's team at each site as per 106 107 the inclusion and exclusion criteria pre-specified in the study protocol. All consecutive patients who visited the facilities for a Covid test and who met inclusion criteria were enrolled in the 108 study and informed consent was obtained. Operators of the Gazelle COVID-19 Test and the RT-109 PCR test were blinded to the results on the different test platform. Additionally, operators tested 110

- a set of blinded, contrived samples to ensure consistency of performance between operators at
- 112 the Bellingham location
- 113

All methods were performed in accordance with the relevant guidelines and regulations. This

paper was drafted according to STROBE and STARD guidelines to ensure the quality of

116 reporting [11, 12].

117

118 Sample Collection

Direct human nasal swab samples were collected from symptomatic subjects and tested
immediately on Gazelle at each site. The swab for RT-PCR was collected immediately before the
swab for the Gazelle test. The swabs for RT-PCR were stored at ambient temperature in Brooks
tubes [should probably provide the item number here] with 0.9% sterile saline according to
Northwest Laboratories protocol, then transported to the laboratory at the end of the day for

testing within 24 hours of collection. The swabs collected in India were also stored in sterilesaline and tested within 24 hours of collection.

126

127 Gazelle Covid-19 Test

Gazelle COVID-19 (Figure 1) is a fluorescent lateral flow immunoassay and accompanying Reader intended for the detection of nucleocapsid antigen from SARS-CoV-2 in nasal swab specimens who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset. The Gazelle COVID-19 Test detects COVID-19 nucleocapsid protein in dual nasal mid-turbinate swab specimens. The Reader is equipped with LEDs and is capable of reading both colorimetric and certain fluorescent lateral flow assays.

134

135 *RT-PCR Procedure*

136 Northwest Laboratories, USA: Confirmation of COVID-19 status was done by using the

137 TaqPath[™] COVID-19 Combo Kit (ThermoFisher Scientific, Pleasanton, CA, USA - Document:

138 MAN0019181 Rev. A.0. March 12, 2020.). RT-PCR assays and analysis were performed

139 following the instructions of the manufacturer using Northwest Laboratory's 7500 Fast Real-

140 Time PCR System Thermocycler (Applied Biosystems, CA, USA). This system was validated

141 via correlation studies with the Washington State Public Health Laboratory using a test system

142 authorized for emergency use by the FDA. Briefly, the conditions of the thermal profile

143 followed several specific steps: (1) 25°C for 2 min; (2) 53°C for 10 min; (3) 95°C for 2 min (4)

40 cycles at 95°C for 3 s, and 60°C for 30 s. According to the instructions of the manufacturer in

145 N-target, the Ct value <37 or two replicates with Ct values of 38 were considered positive; Ct

146 values >39 were considered negative. An exogenous control was included in all reactions using

primers and probe specifically directed at MS2-Phage genomic RNA, obtained from TaqPath[™]

148 COVID-19 Combo Kit. Furthermore, positive, negative, and non-template controls were

149 included in each run. A Ct value <30 in the positive control and no Ct values in negative and

150 non-template controls were considered to validate runs.

151 Bio Diagnostics laboratory and Acu-MDx Laboratory and Research Center Pvt. Ltd

152 *Diagnostics, India*: Confirmation of COVID-19 status was done by using the Taq Path Covid

153 RT-PCR kit (Applied Biosystems; Document No: 100033995 Rev. B.0.Pub No. MAN0014069).

154 RT-PCR assays and analysis were performed following the instructions of the manufacturer

using Quantstudio 5 RT-PCR Instrument (Applied Biosystems). Briefly, the conditions of the

- thermal profile followed several specific steps: (1) 25°C for 2 min; (2) 53°C for 10 min; (3) 95°C
- 157 for 2 min (4) 40 cycles at 95°C for 3 s, and 60°C for 30 s. According to the instructions of the
- 158 manufacturer in N-target, the Ct value <35; Ct values >35 were considered negative.
- 159
- 160 Data collection and Statistical Analysis

Operators of the Gazelle test were the employees certified by the respective laboratories at taking 161 nasal swabs with no formal training. The operators were provided the Instructions for Use (IFU). 162 No additional training on the Gazelle test was provided to the operators. Following Gazelle 163 COVID-19 Test, data from the Gazelle Reader was sent to Hemex to be analyzed by the Gazelle 164 165 Covid-19 algorithm. RT-PCR results were recorded at the testing laboratory according to its procedures. They were also recorded in a Google spreadsheet provided by the sponsor. Other 166 167 Case Report Form information was entered by the test site and then copied into the Google spreadsheet. 168

169

All test results recorded in the spreadsheets were reviewed and verified for completeness and
entry accuracy by the Investigator and Hemex Monitor (Hemex employee responsible for
monitoring study quality). Test results were verified daily to ensure they were complete and error

- 173 free.
- 174

175 The diagnostic performance Gazelle Covid-19 test was assessed using sensitivity, specificity,

- 176 positive predictive value (PPV) and negative predictive value (NPV). Data was analyzed for
- sensitivity or PPA (i.e., the probability that the assay will be positive when the comparator assay
- is positive; sensitivity = comparator positive (TP)/(TP + false negative [FN]) $\times 100\%$) and
- specificity or NPA (i.e., the probability that the assay will be negative when the comparator
- assay is negative; specificity = comparator negative $(TN)/(TN + (false positive [FP]) \times 100\%)$.

181

182 **RESULTS**

183 A total of 1090 potential participants were screened in India and 458 were screened at

184 Bellingham site in the United States. Patient screening and enrolment details are presented in the

185 flow chart (Figure 2).

186 Overall, data from 1486 participants was analyzed. Mean (range) age of study participants from

- the Bellingham site was 32.8 (2-90) years and 250 (58.4%) were female. Mean (range) age of
- study participants from India was 35.5 (4-94) years and 304 (28.7%) were female. A total of 133
- tests were RT-PCR positive and 1353 were RT-PCR negative. Gazelle Test results and
- 190 performance in comparison to RT-PCR is presented in **Table 1 and Table 2**, respectively.
- 191
- 192 A total of 23 operators performed 428 tests (range, 1-59) at the Bellingham site. As a quality 193 control measure, consistency of performance among test operators was also assessed at the 194 Bellingham site. A total of 24 Gazelle tests (4 Gazelle tests per sample) were run across 6 195 contrived samples (A, B, C D, E, and F). Each of the 4 operators assessed ran one Gazelle test on 196 each of the 6 contrived samples. Three of the contrived samples were negative (samples A, D, 197 and F), and 3 were <2x limit of detection positive (samples B, C, and E). The concentration of 198 the positive samples was 10-50% tissue culture infective dose/mL. The tests were run 199 interspersed with the clinical samples across 2 days (20 October 2021 and 21 October 2021). 200 Gazelle Covid-19 test showed high inter-operator test operator agreement. Gazelle also showed 201 100% accuracy on all the contrived sample testing.
- 202

203 **DISCUSSION**

204

205 Rapid-result testing for SARS-CoV-2 has value in many clinical settings that may not have 206 access to specialized laboratory equipment or personnel and have a need for immediate decision-207 making or counseling the patient according to the results obtained. Here we describe the performance of Gazelle Covid-19 test for the qualitative detection of SARS-CoV-2 in nasal swab 208 209 samples from symptomatic subjects. Gazelle Covid-19 test demonstrated high diagnostic potential with low false positive/negative rates and a detection accuracy of 99.4% compared to 210 211 the RT-PCR. Gazelle Covid-19 test meets the criteria recommended in WHO interim guidance for diagnosis of SARS-CoV-2 infection (at least 80% sensitivity and 97% specificity) with rapid 212 213 antigen assays [13].

214

An optimal Covid-19 test would detect replicating or transmissible virus, avoiding prolonged
positivity of RT-PCR after infectiousness has resolved. There is currently no gold standard test

217 that identifies infectious subjects with replicating or transmissible virus. SARS-CoV-2 218 nucleocapsid antigen is generally detectable in nasal swabs during the acute phase of infection 219 [14]. Positive results indicate the presence of viral antigens, but clinical correlation with patient 220 history and other diagnostic information is necessary to determine disease status. In this context, 221 antigen testing has been shown to have higher accuracy among specimens with positive viral culture, correlating with the period when infectious virus is present [15]. 222 223 Persons who know their positive test result can isolate sooner, and where appropriate contact tracing can be initiated sooner and be more effective. Asymptomatic SARS-CoV-2 infected 224 225 subjects were not included in the study, and lower viral loads are likely to reduce sensitivity relative to PCR, though these cases are also less likely to transmit (REF). A study to assess the 226 227 performance of Gazelle Covid-19 test in an asymptomatic population is currently underway. This study adds to the growing evidence of the performance of different rapid SARS-CoV-2 antigen 228 detections, especially in the community settings. Gazelle Covid-19 test is easy to perform with 229 minimal training or previous laboratory testing experience and is thus a feasible solution to 230 implement at sites requiring a POC solution. Inter-operator test operator agreement in the target 231 232 clinical population and environment indicated that the device operation and the results are reproducible. 233

234

This study has some limitations. subjects with invalid results were not able to be retested because participants left the facility before test results were available. A total of 2.6% of the initial Gazelle Covid-19 test results were either invalid or canceled and would have required patient retesting in accordance with the IFU. Re-collection of samples and retesting would be expected to further reduce the invalid rate, but this was not possible during our study. Discrepant results observed between the Gazelle Covid-19 test and reference RT-PCR could not be further clarified, as further samples were not available for retesting.

242

243

In summary, herein we have shown that the Gazelle Covid-19 test using a nasal swab collection method is highly accurate and has close concordance with RT-PCR based assay for detection of SARS-CoV-2 in a POC setting. Gazelle Covid-19 test has potential to quickly and effectively

247	screen all symptomatic patients suspected of COVID-19 at POC, enabling rapid detection and			
248	isolation of people most likely to pose an infectious risk.			
249				
250				
251	DATA AVAILABILITY STATEMENT			
252	The datasets generated during and/or analyzed during the current study are available from the			
253	corresponding author on reasonable request.			
254				
255	ETHICS STATEMENT			
256	Institutional Review Board approval was obtained by the sponsor before starting the study in the			
257	United States (WCG IRB Tracking number: 20212857). Study protocol from India was approved			
258	by the Ethics Committee of International Institute of Sleep Sciences (Reg No:			
259	ECR/177/Indt/MH-2014/RR-19). Informed consents were obtained from all study participants.			
260				
261	FUNDING			
262	The funding for the study was provided by Hemex Health, Inc., USA.			
263				
264	ACKNOWLEDGMENTS			
265	None			
266				
267	CONFLICT OF INTEREST			
268	ROG and KT were hired as consultants by Hemex Health to execute this study. AM is a board			
269	member of HemexDx, a subsidiary of Hemex Health in India.			
270				
271	REFERENCES			
272				
273	1. World Health Organization (WHO). WHO Director-General's opening remarks at the			
274	media briefing on COVID-19: 11 March 2020. Published March 11, 2020. Accessed			
275	March 11, 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-			
276	opening-remarks-at-the-media-briefing-on-covid-1911-march-2020.			

277 2. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical 278 samples. Lancet Infect Dis 2020;20:411-2. 279 3. Reynard C, Allen JA, Shinkins B, Prestwich G, Goves J, Davies K, Body R. COVID-19 rapid diagnostics: practice review. Emergency Medicine Journal. 2022 Jan 1;39(1):70-6. 280 281 4. Kretzschmar ME, Rozhnova G, Bootsma MC, van Boven M, van de Wijgert JH, Bonten MJ. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a 282 283 modelling study. The Lancet Public Health. 2020 Aug 1;5(8):e452-9. 5. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, 284 Parker R. 2020. Test sensitivity is secondary to frequency and turnaround time for 285 COVID-19 surveillance. Science advances. 2021 Jan 1;7(1):eabd5393. 286 6. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jaton K, Greub G. Diagnostic 287 strategies for SARS-CoV-2 infection and interpretation of microbiological results. 288 Clinical Microbiology and Infection. 2020 Sep 1;26(9):1178-82. 289 7. Owusu D, Pomeroy MA, Lewis NM, Wadhwa A, Yousaf AR, Whitaker B, et al. 290 Persistent SARS-CoV-2 RNA Shedding without Evidence of Infectiousness: A Cohort 291 292 Study of Individuals with COVID-19. J Infect Dis 2021; jiab107. 8. World Health Organization. 2020. Global research collaboration for infectious disease 293 preparedness—COVID 19: Public Health Emergency of International Concern (PHEIC). 294 295 Global research and innovation forum: towards a research roadmap, 02/11/2020-296 02/12/2020. World Health Organization, Geneva, Switzerland. https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-297 international-concern-(pheic)-global-research-and-innovation-forum. 298 299 9. Laboratory Testing for Coronavirus Disease 2019 (COVID-19) in Suspected Human 300 Cases: Interim Guidance (World Health Organization, 2 March 2020); https://apps.who.int/iris/handle/10665/331329. 301 302 10. Shrivas S, Patel M, Kumar R, Gwal A, Uikey R, Tiwari SK, Verma AK, Thota P, Das A, Bharti PK, Shanmugam R. Evaluation of Microchip-Based Point-Of-Care Device 303 304 "Gazelle" for Diagnosis of Sickle Cell Disease in India. Frontiers in Medicine. 2021;8. 11. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole 305 C, Schlesselman JJ, Egger M. STROBE Initiative. Strengthening the Reporting of 306

307	Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS
308	Med. 2007, 4, e297.
309	12. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L, Levine
310	D, Reitsma JB, de Vet HC, et al. STARD 2015 guidelines for reporting diagnostic
311	accuracy studies: Explanation and elaboration. BMJ Open 2016, 6, e012799.
312	13. World Health Organisation Advice on the Use of Point-of-Care Immunodiagnostic Tests
313	for COVID-19. 2020. https://www.who.int/news-room/commentaries/detail/advice-on-
314	the-use-of-point-of-care-mmunodiagnostic-tests-for-covid-19
315	14. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z,
316	Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J,
317	Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients
318	infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497-506.
319	15. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two
320	Community-Based Testing Sites — Pima County, Arizona, November 3–17, 2020.
321	https://www.cdc.gov/mmwr/volumes/70/wr/mm7003e3.htm
322	
323	AUTHOR CONTRIBUTIONS
324	
325	AM, AG and PK helped with the planning and execution of clinical study in India and BS, ROG,
326	KT and RRF helped with the planning and execution of the clinical study in the US. AG, PK,
327	BS, ROG and KT helped with subject recruitment, nasal swab collection, and testing. All the
328	authors authored and edited the manuscript and helped in preparing the tables, figures, figure
329	captions, and supplementary information.
330	
331	
332	
333	
334	
335	
336	
337	

		RT-PCR confir	med COVID-19		
United States					
		Positive	Negative	Total	
Gazelle Covid-	Positive	44	1	45	
19 Test	Negative	2	381	383	
19 Test	Total	46	382	428	
		India			
		Positive	Negative	Total	
Gazelle Covid-	Positive	85	3	88	
	Negative	3	967	970	
19 Test	Total	88	970	1058	
		Combined	I		
		Positive	Negative	Total	
Cazalla Cavid	Positive	129	4	133	
Gazelle Covid-	Negative	5	1348	1353	
19 Test	Total	134	1352	1486	

Table 1. Results of Gazelle Covid-19 Test in comparison to RT-PCR

339

340

Table 2. Performance of Gazelle Covid-19 Test in comparison to RT-PCR

	United States	India	Combined % (n/N)
Sensitivity	95.7% (44/45)	96.6% (85/88)	96.3% (129/134)
Specificity	99.7% (381/383)	99.7% (967/970)	99.7% (1348/1352)
Positive Predictive Value (PPV)	99.3% (425/428)	99.7% (967/970)	97.0% (129/133)

	Negative Predictive Value (NPV)	97.8% (44/45)	96.6% (85/88)	99.6% (1348/1353)
	Accuracy	99.5% (381/383)	99.7% (967/970)	99.4% (1477/1486)
342				
343				
344				
345				
346				
347				
348 349				
350				
351				
352				
353				
354				
355				
356				
357				
358				
359				
360				
361 362				
363				
364				

Figure 1. Gazelle Covid-19 Reader and interpretation of results







- **Figure 2**. Patient screening and enrolment flowchart

